Pathfinder Cell Therapy, Inc.
PFND
$0.00
$0.000.00%
OTC PK
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 138.00K | 116.00K | 191.00K | 165.00K | 187.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 209.00K | 144.00K | 204.00K | 218.00K | 213.00K |
| Operating Income | -209.00K | -144.00K | -204.00K | -218.00K | -213.00K |
| Income Before Tax | -289.00K | -222.00K | -276.00K | -293.00K | -284.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -289.00K | -222.00K | -276.00K | -293.00K | -284.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -289.00K | -222.00K | -276.00K | -293.00K | -284.00K |
| EBIT | -209.00K | -144.00K | -204.00K | -218.00K | -213.00K |
| EBITDA | -208.00K | -143.00K | -203.00K | -218.00K | -212.00K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 667.16M | 667.16M | 667.16M | 667.16M | 667.16M |
| Average Diluted Shares Outstanding | 667.16M | 667.16M | 667.16M | 667.16M | 667.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |